ANRO enters its May 21 earnings event with a striking and sudden shift in options sentiment — one that stands in sharp contrast to the stock's recent price weakness and a track record of post-earnings declines.
The clearest signal heading into Thursday is the options market. The put/call ratio dropped to 0.37 on May 18, against a 20-day mean near 0.74 — more than two standard deviations below average, the most call-skewed reading in nearly a year. This is a rare burst of bullish options positioning for a stock that spent most of April and early May running a PCR close to 0.87–0.89. That pivot happened in a single session, suggesting traders are making a deliberate directional bet ahead of the print rather than simply rolling hedges.
The shift arrives against a difficult price backdrop. ANRO has fallen roughly 11% over the past month to $22.98, including a 5.3% drop on the week. That pressure matters because the stock's recent earnings history has been consistently unkind: each of the three prior data events triggered a negative one-day reaction, ranging from -4.2% to -9.2%. The May 12 catalyst in the history — a -6.8% session — and the March event, which added a further -7% over the subsequent five days, illustrate how the market has repeatedly punished the name around announcements. The call-heavy positioning now running through the options market is therefore a meaningful bet against that pattern repeating.
Short interest tells a less combative story. Bears have been trimming sharply — SI dropped 27% on the week to roughly 5% of the free float, the lowest level in the history window. Borrow conditions offer no additional squeeze pressure: the cost to borrow has eased to under 1%, and availability is at 717% of estimated short interest, meaning there are more than seven shares available in the lending pool for every share currently borrowed. The lending market is loose.
Where analysts sit reflects a genuine disagreement. Baird trimmed its target to $36 on May 18 while holding its Outperform rating — a mild cooling rather than a reversal. Wedbush, carrying a Neutral, nudged its target up to $24, barely above the current price. HC Wainwright stands firmly at a $50 Buy. The mean target of ~$35 implies roughly 54% upside from current levels, but the range — from $24 to $50 — underscores that the Street has not converged on a view. Bulls point to Alto's biomarker-driven precision psychiatry platform as a genuine differentiator in a space littered with failed me-too drugs; bears flag the binary risks of clinical-stage development, regulatory uncertainty, and reliance on EEG-based diagnostics that have yet to achieve broad clinical acceptance.
Thursday's print will test whether the sudden swing toward calls reflects genuine confidence in pipeline progress — or simply a pre-earnings position that has repeatedly been unwound.
See the live data behind this article on ORTEX.
Open ANRO on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
